Mayne Pharma GroupMAYNF 48 Net Current Asset Value is $-2.02 as of Dec. 2025. GuruFocus rates MAYNF with a GF Score™ of 48/100 and a GF Value™ of $3.70 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 75 Medical Distribution companies, Mayne Pharma Group ranks worse than 1333332% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Mayne Pharma Group's net current asset value per share for the quarter that ended in Dec. 2025 was $-2.02.
The historical rank and industry rank for Mayne Pharma Group's Net Current Asset Value or its related term are showing as below:
MAYNF's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Distribution industry.
Industry Median: 3.29 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Mayne Pharma Group (OTCPK:MAYNF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Mayne Pharma Group Net Current Asset Value Related Terms
Mayne Pharma Group Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Mayne Pharma Group's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MAYNF vs MCK, CAH, COR: Net Current Asset Value Comparison
For the Medical Distribution subindustry, Mayne Pharma Group's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mayne Pharma Group Price-to-Net-Current-Asset-Value vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Mayne Pharma Group's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Mayne Pharma Group's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $-2.02 mean?
Mayne Pharma Group (MAYNF) has a Net Current Asset Value of $-2.02 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Mayne Pharma Group and its competitors. According to the industry distribution chart, Mayne Pharma Group ranks #999999 out of 75 companies in the Medical Distribution industry.
Is Mayne Pharma Group's Net Current Asset Value too high?
Mayne Pharma Group's current Net Current Asset Value is $-2.02. Based on the distribution chart, Mayne Pharma Group ranks #999999 out of 75 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Mayne Pharma Group has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mayne Pharma Group's Net Current Asset Value compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Mayne Pharma Group ranks #999999 out of 75 companies for Net Current Asset Value. This places Mayne Pharma Group in the lower half of its industry. The industry median Net Current Asset Value is 3.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Distribution company?
The median Net Current Asset Value among Medical Distribution companies is 3.29, based on 75 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Mayne Pharma Group and its competitors. For the Medical Distribution industry, the median Net Current Asset Value is 3.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mayne Pharma Group's current Net Current Asset Value is $-2.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mayne Pharma Group stock overvalued right now?
Based on GuruFocus' analysis, Mayne Pharma Group (MAYNF) is currently considered Possible Value Trap. The stock's GF Value™ is $3.70, compared to a current price of $1.65 — trading 55.4% below its estimated fair value. The current Net Current Asset Value is $-2.02. Mayne Pharma Group's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Mayne Pharma Group (MAYNF), the current Net Current Asset Value is $-2.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mayne Pharma Group (MAYNF) Overvalued in 2026?
Based on GuruFocus' analysis, Mayne Pharma Group stock appears to be undervalued.
The current stock price of $1.65 is trading 55.4% below its estimated GF Value™ of $3.70.
GuruFocus considers Mayne Pharma Group to be Possible Value Trap.
Key valuation signals for MAYNF:
Net Current Asset Value: $-2.02
GF Value™: $3.70 vs. price of $1.65 (55.4% below fair value)
No single metric tells the full story. See the MAYNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women's Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women's Health segment distributes branded women's health products in the U.S. International's segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
48GF Score
Get the complete analysis for MAYNF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAYNF has been successfully added to your 
